42,471 Shares in Arrowhead Pharmaceuticals, Inc. $ARWR Bought by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D purchased a new position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 42,471 shares of the biotechnology company's stock, valued at approximately $2,820,000.

Several other large investors also recently bought and sold shares of the business. Sage Rhino Capital LLC bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth $348,000. FengHe Fund Management Pte. Ltd. bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth $17,706,000. Pictet Asset Management Holding SA increased its position in Arrowhead Pharmaceuticals by 253.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,028,736 shares of the biotechnology company's stock worth $68,636,000 after purchasing an additional 737,713 shares during the last quarter. UBS Group AG increased its position in Arrowhead Pharmaceuticals by 7.5% in the fourth quarter. UBS Group AG now owns 987,287 shares of the biotechnology company's stock worth $65,546,000 after purchasing an additional 69,104 shares during the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in Arrowhead Pharmaceuticals in the fourth quarter worth $1,816,000. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Trading Down 1.9%

ARWR stock opened at $74.93 on Wednesday. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $12.44 and a twelve month high of $77.90. The stock has a market capitalization of $10.49 billion, a price-to-earnings ratio of 48.97 and a beta of 1.28. The firm's fifty day simple moving average is $63.70 and its two-hundred day simple moving average is $59.78.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts' consensus estimates of $0.60 by ($0.38). The firm had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The company's revenue was up 10461.3% on a year-over-year basis. During the same quarter last year, the firm earned ($1.39) EPS. As a group, analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.37 earnings per share for the current year.

Analysts Set New Price Targets

ARWR has been the topic of several research reports. HC Wainwright restated a "buy" rating and issued a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, March 25th. Weiss Ratings upgraded shares of Arrowhead Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Friday, February 6th. JPMorgan Chase & Co. initiated coverage on shares of Arrowhead Pharmaceuticals in a research report on Friday, May 1st. They issued an "overweight" rating and a $88.00 price target on the stock. B. Riley Financial boosted their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the stock a "buy" rating in a research report on Thursday, January 22nd. Finally, The Goldman Sachs Group boosted their price target on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a "neutral" rating in a research report on Wednesday, January 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $84.20.

Insider Transactions at Arrowhead Pharmaceuticals

In other news, insider James C. Hamilton sold 10,000 shares of the company's stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the transaction, the insider directly owned 226,958 shares in the company, valued at approximately $17,021,850. This represents a 4.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Daniel Joseph Apel sold 13,095 shares of the company's stock in a transaction dated Wednesday, April 22nd. The stock was sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the transaction, the chief financial officer owned 162,905 shares in the company, valued at approximately $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 33,095 shares of company stock worth $2,326,228. Company insiders own 3.60% of the company's stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company's approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company's pipeline includes multiple candidates in various stages of development.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.